Scarica l'app Stockscreener
2.41
4.78%
0.11
Precedente Chiudi:
$2.30
Aprire:
$2.32
Volume 24 ore:
275.36K
Relative Volume:
0.64
Capitalizzazione di mercato:
$227.95M
Reddito:
$72.66M
Utile/perdita netta:
$34.86M
Rapporto P/E:
6.5847
EPS:
0.366
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
+2.55%
1M Prestazione:
+0.84%
6M Prestazione:
+44.31%
1 anno Prestazione:
+67.36%
Intervallo 1D:
$2.315
$2.43
Intervallo di 1 settimana:
$2.17
$2.445
Portata 52W:
$1.295
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.41 | 225.11M | 72.66M | 34.86M | -62.91M | 0.366 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Iniziato | Lake Street | Buy |
| 2026-01-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-13 | Iniziato | Oppenheimer | Outperform |
| 2022-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-26 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-05-13 | Iniziato | Stifel | Buy |
| 2020-05-07 | Iniziato | SVB Leerink | Outperform |
| 2020-04-22 | Iniziato | ROTH Capital | Buy |
| 2020-03-24 | Iniziato | SunTrust | Buy |
| 2020-01-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Iniziato | Oppenheimer | Outperform |
| 2016-02-01 | Ripresa | Oppenheimer | Outperform |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2015-04-23 | Ripresa | Jefferies | Buy |
| 2015-04-21 | Iniziato | Oppenheimer | Outperform |
| 2014-02-07 | Iniziato | MLV & Co | Buy |
| 2009-12-28 | Reiterato | Cantor Fitzgerald | Buy |
| 2009-07-29 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Compugen Ltd Borsa (CGEN) Ultime notizie
Compugen Ltd (CGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Compugen Ltd (CGEN) Income Statement - TradingKey
CGEN|Compugen Ltd|Price:2.365|Chg%:+0.085 - TradingKey
Compugen Ltd (CGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CGEN|Compugen Ltd|Price:2.375|Chg%:+0.095 - TradingKey
CGEN|Compugen Ltd|Price:2.430| - TradingKey
Compugen Ltd (CGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compugen Ltd (CGEN) Cash Flow - TradingKey
TradingKey - TradingKey
CGEN|Compugen Ltd|Price:2.280|Chg%:-0.060 - TradingKey
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance UK
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Compugen to Participate in BTIG Biotechnology Conference 2026 - marketscreener.com
Compugen (CGEN) to Release Q2 Financial Results on August 3, 202 - GuruFocus
Compugen's Cancer Immunotherapy Update Is Set for Aug. 3 - Stock Titan
Compugen to release Q2 2026 results, host conference call - Bitget
Compugen (CGEN) SVP Levine exercises options and sells 1,875 shares under plan - Stock Titan
CGEN Stock Update: Virtual Meeting Announcement - GuruFocus
Compugen Ltd. (CGEN) Surges 3.5% Amid Biotech Sector Renewed InterestBollinger Expansion - dars.gov.et
Compugen Q1 2026 Earnings: EPS Misses Estimates, No Revenue ReportedEarnings Power Value - dars.gov.et
Compugen (CGEN) Edges Lower as Shares Test Support Near $2.03Gamma Squeeze - dars.gov.et
CGEN Q1 2026 Earnings: Narrowing Net Loss and Pipeline Progress Fuel OptimismGuidance Revision Trend - dars.gov.et
Compugen Ltd (CGEN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to EBITDA forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Enterprise value to revenue forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Enterprise value to EBIT forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Price to sales forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Compugen Ltd. Actuals & Estimates (NASDAQ:CGEN) - TradingView
Compugen Ltd (CGEN) Institutional Confidence - TradingKey
Compugen Ltd. Actuals & Estimates (TASE:CGEN) - TradingView
CGEN Forecast — Price Target — Prediction for 2027 - TradingView
Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Compugen presents ovarian cancer trial poster at ESMO meeting - Investing.com UK
Compugen presents ovarian cancer trial poster at ESMO meeting By Investing.com - Investing.com South Africa
Compugen spotlights COM701 ovarian trial at ESMO congress - Stock Titan
Compugen presents trial data on COM701 for ovar... - Pluang
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions - Yahoo Finance UK
Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compugen Ltd (CGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CGEN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage Continues; Stock DeclinesStrong Earnings Momentum - newsline.com
CGEN Q1 2026 Earnings: EPS Misses Estimates amid R&D FocusRevenue Beat Analysis - newsline.com
Compugen Ltd. (CGEN) Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues DevelopmentBuyback Announcement Report - dars.gov.et
Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu - GuruFocus
COMPUGEN ($CGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Compugen to present ovarian cancer trial poster at ESMO - Investing.com UK
Compugen to present ovarian cancer trial poster at ESMO By Investing.com - Investing.com South Africa
Compugen Ltd Azioni (CGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Compugen Ltd Azioni (CGEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levine Zurit | SVP, Business Development |
Jul 09 '26 |
Sale |
2.50 |
1,875 |
4,688 |
29,375 |
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Option Exercise |
1.15 |
2,000 |
2,300 |
31,375 |
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Sale |
3.20 |
2,000 |
6,400 |
29,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Option Exercise |
0.83 |
5,000 |
4,146 |
16,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Sale |
3.20 |
5,000 |
16,000 |
11,375 |
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):